
BTIG analyst Julian Harrison maintained a Buy rating on Avalo Therapeutics yesterday and set a price target of $10.00. Julian Harrison’s Buy rating is based on several factors supporting Avalo
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| AVTX | Avalo Therapeutics | 6.81 | -11.07 | -61.91% |
| Name | Price | % Change | |
|---|---|---|---|
| $6.81 | -61.91% |

BTIG analyst Julian Harrison maintained a Buy rating on Avalo Therapeutics yesterday and set a price target of $10.00. Julian Harrison’s Buy rating is based on several factors supporting Avalo

H.C. Wainwright analyst Mitchell Kapoor has reiterated their neutral stance on AVTX stock, giving a Hold rating on October 23. Mitchell Kapoor’s rating is based on a balance between Avalo

Wedbush lowered the firm’s price target on Avalo Therapeutics (AVTX) to $20 from $22 and keeps an Outperform rating on the shares after the company reported third quarter financials ahead

BofA analyst Alec Stranahan lowered the firm’s price target on Avalo Therapeutics (AVTX) to $24 from $29 and keeps a Buy rating on the shares. Published first on TheFly –

Avalo Therapeutics ( ($AVTX) ) just unveiled an announcement. On November 5, 2026, Avalo Therapeutics entered an at-the-market agreement with Jefferies covering potential sales of common stock worth up to

08:32 EST Avalo Therapeutics (AVTX) files automatic mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks

“LOTUS provides a strong clinical foundation for advancing abdakibart toward registrational development in hidradenitis suppurativa,” said Garry Neil, Chief Executive Officer of Avalo. “The efficacy and safety results observed across

Oppenheimer lowered the firm’s price target on Avalo Therapeutics (AVTX) to $16 from $35 and keeps an Outperform rating on the shares. Published first on TheFly – the ultimate source

Wedbush lowered the firm’s price target on Avalo Therapeutics (AVTX) to $22 from $34 and keeps an Outperform rating on the shares. The firm believes topline results from the Phase

As previously reported, Guggenheim analyst Yatin Suneja downgraded Avalo Therapeutics (AVTX) to Neutral from Buy and removed the firm’s prior price target after AbbVie’s (ABBV) Phase 3 INTREPID study of
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| hold | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Nov 5, 2026 | ||||
| buy | Reiterated | Oct 26, 2026 | ||||
| hold | Downgraded | Oct 23, 2026 | ||||
| buy | Reiterated | Oct 1, 2026 | ||||
| buy | Initiated | Jul 6, 2026 | ||||
| buy | Reiterated | Jun 11, 2026 | ||||
| buy | Reiterated | May 15, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 31, 2027TBA | $412.28M | $-0.45 | $0.00 | -0.09 | -2.32 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.